tiletamine hydrochloride has been researched along with Bone Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, Y; Hua, X; Jiang, C; Wan, D; Wang, T | 1 |
| Borges, KS; Castro-Gamero, AM; da Silva Silveira, V; de Paula Gomes Queiroz, R; Lira, RC; Scrideli, CA; Tone, LG; Umezawa, K; Valera, FC | 1 |
2 other study(ies) available for tiletamine hydrochloride and Bone Cancer
| Article | Year |
|---|---|
Cell cycle arrest and apoptosis induced by aspidin PB through the p53/p21 and mitochondria-dependent pathways in human osteosarcoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Caspase 3; Caspase 9; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclohexanones; Female; Heterografts; Humans; Membrane Potential, Mitochondrial; Mice, Nude; Mitochondria; Neoplasm Transplantation; Osteosarcoma; Phloroglucinol; RNA, Small Interfering; S Phase Cell Cycle Checkpoints; Signal Transduction; Tumor Suppressor Protein p53 | 2015 |
Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Cyclohexanones; Doxorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Methotrexate; Mitotic Index; NF-kappa B; Osteosarcoma; Protein Transport | 2012 |